Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

This study has been completed.
Information provided by (Responsible Party):
Hospices Civils de Lyon Identifier:
First received: August 23, 2005
Last updated: July 1, 2014
Last verified: May 2014
In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.

Condition Intervention Phase
Skin Cancer
Kidney Transplantation
Drug: rapamycin
Drug: ciclosporine
Drug: tacrolimus
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • To assess the incidence of new squamous cell carcinoma in kidney transplant recipients [ Time Frame: during 5 years ]

Secondary Outcome Measures:
  • To assess the incidence of other non skin cancer in kidney transplant recipients [ Time Frame: during 5 years ]
  • To assess the graft survival [ Time Frame: during 5 years ]
  • To assess the tolerance of rapamycin [ Time Frame: during 5 years ]

Enrollment: 77
Study Start Date: April 2004
Study Completion Date: May 2014
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
patients receiving Rapamycin
Drug: rapamycin
3 to 5 mg/day
Other Name: Rapamune
Active Comparator: 2
patients receiving anticalcineurin treatment
Drug: ciclosporine
Blood residual level < or = to 125 ng/ml
Drug: tacrolimus
Blood residual level < or = to 8 ng/ml


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First post-transplant squamous cell carcinoma in a kidney transplant recipient under calcineurin inhibitors

Exclusion Criteria:

  • Other squamous cell carcinomas in the past history
  • More than 2 transplantations
  • Patients not under calcineurin inhibitors
  • Unstable graft function
  • Non controlled hyperlipidemia (cholesterol > 7.8 mmol/l or triglycerides > 3.95 mmol/l)
  • Leucopenia < 3000/mm3
  • Thrombocytopenia < 100,000/mm3
  • Liver dysfunction
  • Pregnancy
  • Allergy to macrolides
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00133887

Hôpital Edouard Herriot - Service de Dermatologie
Lyon, France, 69003
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Sylvie EUVRARD, MD Hospices Civils de Lyon
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hospices Civils de Lyon Identifier: NCT00133887     History of Changes
Other Study ID Numbers: 2003.333
Study First Received: August 23, 2005
Last Updated: July 1, 2014

Keywords provided by Hospices Civils de Lyon:
Squamous cell carcinoma
kidney transplant recipients
Skin cancers in kidney transplant recipients

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Skin Diseases
Calcineurin Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents processed this record on May 25, 2017